[1]肖妹英.慢性阻塞性肺疾病合并肺部感染患者病原菌分布及影响因素研究[J].医学信息,2024,37(14):142-145.[doi:10.3969/j.issn.1006-1959.2024.14.029]
　XIAO Mei-ying.Study on Distribution and Influencing Factors of Pathogenic Bacteria in Patients with Chronic Obstructive Pulmonary Disease Complicated with Pulmonary Infection[J].Journal of Medical Information,2024,37(14):142-145.[doi:10.3969/j.issn.1006-1959.2024.14.029]
点击复制

慢性阻塞性肺疾病合并肺部感染患者病原菌分布及影响因素研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年14期
页码:
142-145
栏目:
论著
出版日期:
2024-07-15

文章信息/Info

Title:
Study on Distribution and Influencing Factors of Pathogenic Bacteria in Patients with Chronic Obstructive Pulmonary Disease Complicated with Pulmonary Infection
文章编号:
1006-1959（2024）14-0142-04
作者:
肖妹英
（泰和县中医院检验科，江西 泰和 343700）
Author(s):
XIAO Mei-ying
(Laboratory Department of Taihe County Traditional Chinese Medicine Hospital,Taihe 343700,Jiangxi,China)
关键词:
慢性阻塞性肺疾病; 肺部感染; 病原菌; 糖尿病; 机械通气
Keywords:
Chronic obstructive pulmonary disease; Pulmonary infection; Pathogenic bacteria; Diabetes mellitus; Mechanical ventilation
分类号:
R562
DOI:
10.3969/j.issn.1006-1959.2024.14.029
文献标志码:
A
摘要:
目的 研究慢性阻塞性肺疾病（COPD）合并肺部感染患者的病原菌分布及影响因素。方法 以2020年6月-2022年6月泰和县中医院收治的60例COPD患者为研究对象，其中COPD合并肺部感染患者共30例，设为感染组，另30例患者未发生肺部感染，设为未感染组，统计COPD合并肺部感染患者的病原菌分布情况，分析COPD合并肺部感染的影响因素。结果 30例COPD合并肺部感染患者共培养分离病原菌30株，其中革兰阴性菌最为常见，占76.67%，革兰阳性菌占20.00%，真菌占3.33%。单因素分析显示，感染组与未感染组年龄、住院时间、合并症种类、糖尿病史、吸烟史、抗生素使用种类、抗生素使用时长、是否机械通气比较，差异有统计学意义（P＜0.05）。Logistic回归分析显示，年龄≥60岁、合并症种类≥2种、糖尿病史、抗生素使用时长≥15 d、机械通气是COPD合并肺部感染的独立危险因素。结论 COPD合并肺部感染患者的病原菌分布以革兰阴性菌为主，其年龄、合并症种类、糖尿病史、抗生素使用时长与机械通气是导致COPD合并肺部感染的独立危险因素。
Abstract:
Objective To study the distribution and influencing factors of pathogenic bacteria in patients with chronic obstructive pulmonary disease (COPD) complicated with pulmonary infection.Methods From June 2020 to June 2022, 60 patients with COPD admitted to Taihe County Traditional Chinese Medicine Hospital were selected as the research objects. Among them, 30 patients with COPD complicated with pulmonary infection were set as the infection group, and the other 30 patients without pulmonary infection were set as the uninfected group. The distribution of pathogenic bacteria in patients with COPD complicated with pulmonary infection was counted, and the influencing factors of COPD complicated with pulmonary infection were analyzed.Results A total of 30 strains of pathogenic bacteria were isolated from 30 patients with COPD complicated with pulmonary infection. Among them, gram-negative bacteria were the most common, accounting for 76.67%, gram-positive bacteria accounted for 20.00%, and fungi accounted for 3.33%. Univariate analysis showed that there were statistically significant differences in age, length of hospital stay, types of complications, history of diabetes, history of smoking, types of antibiotics used, duration of antibiotics used, and mechanical ventilation between the infected group and the uninfected group (P<0.05). Logistic regression analysis showed that age≥60 years old, type of comorbidities≥2, history of diabetes, duration of antibiotic use≥15 d, and mechanical ventilation were independent risk factors for COPD complicated with pulmonary infection.Conclusion The distribution of pathogenic bacteria in patients with COPD complicated with pulmonary infection is mainly gram-negative bacteria. Age, type of complications, history of diabetes, duration of antibiotic use and mechanical ventilation are independent risk factors for COPD complicated with pulmonary infection.

参考文献/References:

[1]Xu L,Chen B,Wang F,et al.A Higher Rate of Pulmonary Fungal Infection in Chronic Obstructive Pulmonary Disease Patients with Influenza in a Large Tertiary Hospital[J].Respiration,2019,98(5):1-10.[2]贾晶晶,唐西怀,殷娟.慢性阻塞性肺疾病患者肺部感染的病原学及危险因素研究[J].临床肺科杂志,2019,24(3):477-480.[3]王宁,杨佳佳,王丹丹,等.慢性阻塞性肺疾病急性加重合并呼吸机相关性肺炎患者病原菌分布及血清指标水平变化[J].实用医院临床杂志,2022,19(2):50-53.[4]许龙,谭志霞,李秋烨,等.长沙某医院慢阻肺合并肺部感染患者的病原菌分布及药物敏感性分析[J].激光生物学报,2022,31(5):433-439.[5]于菲,侯玮,孙娟,等.慢性阻塞性肺疾病合并肺部感染患者血浆C3、C4、PCT、免疫球蛋白水平的变化及易感因素分析[J].海南医学,2022,33(19):2452-2455.[6]中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.慢性阻塞性肺疾病诊治指南(2021年修订版)[J].中华结核和呼吸杂志,2021,44(3):170-205.[7]黄琪,邓俊,王宋平.慢性阻塞性肺疾病对肺部感染病原菌分布与耐药性的影响[J].实用药物与临床,2022,25(6):512-516.[8]余苗,徐丹,徐晶晶,等.AECOPD合并肺部感染病原学特点及PCT、CD64感染指数、sTREM-1联合检测早期诊断价值分析[J].武警后勤学院学报(医学版),2021,30(10):41-43.[9]王姣,郭亚君.慢性阻塞性肺疾病急性加重期合并肺部感染病原学及其预后评估[J].中华医院感染学杂志,2021,31(10):1522-1526.[10]Yagyu K,Miyamoto A,Ueda T,et al.Patients With Pulmonary Infections And Chronic Obstructive Pulmonary Disease: A Retrospective Clinical Study Of 170 Cases[J].Respirology,2018,23(2):125.[11]贺晓娇,黎思浓,段程.慢性阻塞性肺疾病稳定期患者肺部感染发生的影响因素[J].中国医药导报,2021,18(10):96-99,112.[12]詹秀英.慢性阻塞性肺疾病患者肺部感染的病原学及危险因素研究[J].中国药物与临床,2020,20(20):3385-3387.[13]肖海励,魏海霞,张胜勇,等.慢性阻塞性肺疾病合并肺部感染患者病原菌分布及影响因素分析[J].中国病原生物学杂志,2022,17(11):1324-1327,1332.[14]陈辅萍.慢性阻塞性肺疾病并发感染性肺炎危险因素分析[J].陕西医学杂志,2020,49(1):102-104.[15]张丽,范忠杰,周凡.慢性阻塞性肺疾病急性加重期肺部感染患者的病原菌分布、耐药性及危险因素分析[J].中国病原生物学杂志,2019,14(12):1456-1459.[16]陈孝谦,齐保龙,张鹏.慢性阻塞性肺疾病肺部感染患者病原学分布特征及影响因素[J].公共卫生与预防医学,2023,34(2):101-104.[17]刘春丽,吴伟东.肺部感染与慢性阻塞性肺疾病急性加重期患者外周血淋巴细胞免疫分型关系[J].临床军医杂志,2019,47(11):1270-1271,1280.[18]陈丽敏,孙荣强.慢性阻塞性肺疾病合并肺部真菌感染的相关危险因素与耐药性分析[J].中国卫生检验杂志,2019,29(23):2906-2909.[19]武红莉,田瑞雪,宁兰丁,等.慢性阻塞性肺疾病患者肺部感染的影响因素分析及血清炎症因子水平变化分析[J].中华医院感染学杂志,2018,28(1):25-28.[20]米婷.慢性阻塞性肺疾病并发呼吸衰竭获得性肺部感染的独立危险因素分析[J].山西医药杂志,2018,47(20):2471-2473.[21]韦永刚,颜红英,肖远红.老年慢性阻塞性肺疾病急性加重合并肺部感染的病原菌分布及高危因素分析[J].中国真菌学杂志,2018,13(3):177-180,183.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
　ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(14):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
　CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(14):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
　WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Journal of Medical Information,2018,31(14):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
　LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(14):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
　LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Journal of Medical Information,2018,31(14):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]丁保锋.胃肠道恶性肿瘤患者术后肺部感染临床分析[J].医学信息,2018,31(11):183.[doi:10.3969/j.issn.1006-1959.2018.11.061]
　DING Bao-feng.Clinical Analysis of Postoperative Pulmonary Infection in Patients with Malignant Gastrointestinal Cancer[J].Journal of Medical Information,2018,31(14):183.[doi:10.3969/j.issn.1006-1959.2018.11.061]
[8]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
　JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Journal of Medical Information,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[9]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响[J].医学信息,2018,31(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
　ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
[10]张善芳,汤 杰.穴位注射联合沙美特罗替卡松粉吸入剂治疗 慢性阻塞性肺疾病稳定期的临床疗效观察[J].医学信息,2018,31(16):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]
　ZHANG Shan-fang,TANG Jie.Clinical Observation of Acupoint Injection Combined with Salmeterol and Fluticasone Powder Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(14):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]
[11]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
　ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(14):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[12]李林华.舒适护理联合全面护理用于ICU慢性阻塞性肺疾病并肺心病患者的效果[J].医学信息,2021,34(12):188.[doi:10.3969/j.issn.1006-1959.2021.12.052]
　LI Lin-hua.The Effect of Comfort Nursing Combined with Comprehensive Care for Patients with Chronic Obstructive Pulmonary Disease and Pulmonary Heart Disease in ICU[J].Journal of Medical Information,2021,34(14):188.[doi:10.3969/j.issn.1006-1959.2021.12.052]
[13]陈菊花.左氧氟沙星与氨溴索联合治疗慢性阻塞性肺疾病合并肺部感染患者的疗效及安全性[J].医学信息,2024,37(24):85.[doi:10.3969/j.issn.1006-1959.2024.24.023]
　CHEN Juhua.Efficacy and Safety of Levofloxacin Combined with Ambroxol in the Treatment of Patients with Chronic Obstructive Pulmonary Disease Complicated with Pulmonary Infection[J].Journal of Medical Information,2024,37(14):85.[doi:10.3969/j.issn.1006-1959.2024.24.023]

更新日期/Last Update: 1900-01-01